Blue Earth Diagnostics Ltd.
Radioactive imaging agent detects prostate cancer recurrence
This article was originally published in Start Up
Identifying the precise anatomical site of recurring prostate cancer determines how the disease is treated, however, the standard of care – a CT scan or MRI scan – accurately detects recurrent cancer only about 10% of the time. Blue Earth Diagnostics Ltd. believes its radioactive imaging agent, fluciclovine (18F), used in conjunction with a positron emission tomography scanner, could allow for a substantially higher detection rate.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.